Proliferative Vitreoretinopathy - Pipeline Review, H2 2016; New Report Launched
Proliferative Vitreoretinopathy (PVR) pipeline therapeutics constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by Companies and remaining by the Universities/Institutes. Proliferative Vitreoretinopathy (PVR) – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Proliferative Vitreoretinopathy (PVR), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
View full press release